Product
Supplier
Encyclopedia
Inquiry
Jinlan 98+ EP/BP/USP Acalabrutinib buy - large image1
Jinlan 98+ EP/BP/USP Acalabrutinib buy - image1

Jinlan 98+ EP/BP/USP Acalabrutinib

4 Inquiries

Unit Price: Get Latest Price
CAS No.:

1420477-60-6

Grade:

medical grade

Content:

98%

Port:

Shanghai/Ningbo/Qingdao

Brand:

Jinlan

Packaging:

25kg/Cardboard Drum

Price valid (until):

2026-04-15

Company Type:
Trader
Location:
China
Qualification:
Main Products:

Peptides,API,Intermediate

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  


    Acalabrutinib

    • CAS: 1420477-60-6
    • Molecular Formula: C₂₄H₂₉N₅O₄
    • Molecular Weight: 447.52 g/mol
    • Synonyms: Calquence, ACP-196
    • Form: Solid powder
    • Storage: 2–8°C; protect from moisture
    • Description: BTK inhibitor. Used in mantle cell lymphoma and chronic lymphocytic leukemia. Less CNS penetration than ibrutinib.

    Basic Info
    Product Name:

    4-[8-Amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinylbenzamide

    Other Name:

    Benzamide,4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-;4-[8-Amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinylbenzamide;Acalabrutinib;ACP 196;(S)-4-[8-Amino-3-[1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-(pyridin-2-yl)benzamide;Calquence;1639823-20-3

    CAS No.:

    1420477-60-6

    Molecular Formula:

    C26H23N7O2

    InChIKeys:

    InChIKey=WDENQIQQYWYTPO-IBGZPJMESA-N

    Exact Mass:

    465.51

    Categories:

    Other Chemical Drugs

    Characteristics

    Hazard Identification

    Classification of the substance or mixture

    Specific target organ toxicity – repeated exposure, Category 2

    GHS label elements, including precautionary statements

    Pictogram(s)
    Signal word

    Warning

    Hazard statement(s)

    H373 May cause damage to organs through prolonged or repeated exposure

    Precautionary statement(s)
    Prevention

    P260 Do not breathe dust/fume/gas/mist/vapours/spray.

    Response

    P319 Get medical help if you feel unwell.

    Storage

    none

    Disposal

    P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Peptides,API,Intermediate

    Location:

    Room 606, Building 1, Fu Yi Commercial Center, Shangcheng District, Hangzhou City, Zhejiang Province - 1

    Payment Terms:

    100% TT in advance

    Average lead Time:

    275

    Total Annual Revenue:

    $1 million-$2.5 million

    Total Employees:

    51-100

    Year of Establishment:

    2020

    Hangzhou Jinlan Pharm-Drugs Technology Co., Ltd (with its export company Hangzhou Royall Import & Export Co.,Ltd.) is located in Hangzhou, Zhejiang Province. Neighboring Ningbo port, Shanghai port, Hangzhou Xiaoshan Int' l Airport and Shanghai Pudong Int' l Airport, the transportation and production environment are excellent. JINLAN PHARMA mainly business includes: 1) API, Pharmaceutical Intermediates, CMO, CRO, CDMO and so on. 2) Pharmaceutical Equipment such as: Distilled Water Machinery, Mixer, Sterilizer and so on.

    JINLAN PHARM focus on:

    ■ Contrast Agent

    ■ Anti-COVID APIs

    ■ Respiratory System APIs

    ■ Anti-tumor & Anti-Cancer APIs

    ■ Anti-Diabetes APIs

    ■ Anti-HCV & Anti-HBV APIs

    ■ Anti-HIV APIs

    ■ Peptides

    ■ Pharmaceutical Intermediates

    ■ CMO, CRO, CDMO

  • Inquiry History
    4 Inquiries
    Country Product Purchase Quantity Date Posted
    India

    Acalabrutinib

    11 KG Apr 21, 2025
    India

    ACALABRUTINIB

    1 KG Jun 4, 2025
    Pakistan

    Acalabrutinib

    1 KG Jun 18, 2025
    India

    Acalabrutinib

    10 KG Apr 14, 2025
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.